Cost-Effectiveness of Clinical Decision Support to Improve CKD Outcomes Among First Nations Australians

Cost-Effectiveness of Clinical Decision Support to Improve CKD Outcomes Among First Nations Australians

Introduction: The Northern Territory (NT) is a hotspot for chronic kidney disease (CKD) and has a high incidence of kidney replacement therapy (KRT). The Territory Kidney Care clinical decision support (CDS) tool aims to improve diagnosis and management of CKD in remote NT, particularly among First...

Full description

Saved in:
Bibliographic Details
Main Authors: Winnie Chen, Kirsten Howard, Gillian Gorham, Asanga Abeyaratne, Yuejen Zhao, Oyelola Adegboye, Nadarajah Kangaharan, Sean Taylor, Louise J. Maple-Brown, Samuel Heard, Mohammad Radwanur Talukder, Abdolvahab Baghbanian, Sandawana William Majoni, Alan Cass, Ali Lloyd, Andrew Bell, Christine Connors, Craig Castillon, David McGuiness, Emma Kennedy, Jenny Jobst, Liz Moore, Molly Shorthouse, Nathan Garrawurra, Nathan Rosas, Pratish George, Rama Nair, Rebecca Bond, Robert Forbes, Ronald Ogilvie, Satpinder Daroch, Velma King
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Kidney International Reports
Subjects:
Aboriginal health
chronic kidney disease
clinical decision support
cost
cost-effectiveness
economic evaluation
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492401996X
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The Northern Territory (NT) is a hotspot for chronic kidney disease (CKD) and has a high incidence of kidney replacement therapy (KRT). The Territory Kidney Care clinical decision support (CDS) tool aims to improve diagnosis and management of CKD in remote NT, particularly among First Nations Australians. We model the cost-effectiveness of the CDS versus usual care. Methods: Taking a health care funder perspective, we modeled a cohort of people from remote NT at risk of or with CKD, as of January 1, 2017. A Markov cohort model was developed using 6 years of observed patient-level data (2017–2023), extrapolated to a 15-year time horizon. The CDS tool was modeled to improve CKD diagnosis (scenario 1), improve management (scenario 2), or improve both diagnosis and management (scenario 3). Results: The remote NT cohort consisted of 23,195 people, predominantly (89%) First Nations, with a mean age of 42 years. Scenario 3 (improved diagnosis and management) was most cost-effective at an incremental cost-effectiveness ratio (ICER) of $96,684 per patient avoiding KRT, $30,086 per patient avoiding death. Scenario 1 (improved diagnosis) was less cost-effective, and scenario 2 (improved management) was the least cost-effective. The ICER per quality-adjusted life years (QALYs) gained ranged from $3427 (scenario 3) to $63,486 (scenario 2). Conclusion: Territory Kidney Care is highly cost-effective when it supports early diagnosis of CKD and increases optimal management in diagnosed patients. These results support investing in CDS tools, implemented in strong partnerships, to improve outcomes in settings with a high burden of CKD.
ISSN:2468-0249

Similar Items